Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18303099rdf:typepubmed:Citationlld:pubmed
pubmed-article:18303099lifeskim:mentionsumls-concept:C0003232lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C0010674lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C2709248lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C0686904lld:lifeskim
pubmed-article:18303099lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:18303099pubmed:issue1lld:pubmed
pubmed-article:18303099pubmed:dateCreated2008-2-27lld:pubmed
pubmed-article:18303099pubmed:abstractTextPulmonary exacerbations (P Exs) are important in cystic fibrosis (CF). They are very common, and are associated with poor quality of life. P Exs are regarded as an important end point in clinical trials. Risk factors associated with increase in P Exs have not been examined at a large scale. This study investigates factors associated with P Exs in a large cohort of adolescent and adult patients.lld:pubmed
pubmed-article:18303099pubmed:languageenglld:pubmed
pubmed-article:18303099pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18303099pubmed:citationSubsetIMlld:pubmed
pubmed-article:18303099pubmed:statusMEDLINElld:pubmed
pubmed-article:18303099pubmed:issn1479-9723lld:pubmed
pubmed-article:18303099pubmed:authorpubmed-author:GiletJJlld:pubmed
pubmed-article:18303099pubmed:authorpubmed-author:JaradN ANAlld:pubmed
pubmed-article:18303099pubmed:issnTypePrintlld:pubmed
pubmed-article:18303099pubmed:volume5lld:pubmed
pubmed-article:18303099pubmed:ownerNLMlld:pubmed
pubmed-article:18303099pubmed:authorsCompleteYlld:pubmed
pubmed-article:18303099pubmed:pagination29-33lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:meshHeadingpubmed-meshheading:18303099...lld:pubmed
pubmed-article:18303099pubmed:year2008lld:pubmed
pubmed-article:18303099pubmed:articleTitleRisk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis.lld:pubmed
pubmed-article:18303099pubmed:affiliationThe Adult CF Centre, Bristol Royal Infirmary, Bristol, UK. Nabil.Jarad@ubht.nhs.uklld:pubmed
pubmed-article:18303099pubmed:publicationTypeJournal Articlelld:pubmed